NCT02879630Completed
Prospective Evaluation of Adjusted Body Weight Dosing of Acyclovir in Obesity
Source: ClinicalTrials.gov · Last updated 16 Apr 2026
Brief summary (registry, in English)
Patients receiving acyclovir as standard of care will be enrolled into this study. The currently recommended dosing strategy at our institution for obese patients is to receive intravenous acyclovir dosed per an adjusted body weight \[IBW + 0.4(TBW-IBW)\]. They will have blood drawn once prior to the first dose of acyclovir and 10 times thereafter, over a total time period of 12 hours. These patients will already be hospitalized for other reasons, and will not be required to make additional trips to the hospital. A total of approximately 4-5 tablespoons of blood will be drawn for this study. Ten obese patients and 10 matched control (non-obese) patients will be enrolled.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 13 (actual)
- First submitted
- 18 Aug 2016
- Start date
- 28 Nov 2016
- Primary completion date
- 16 Feb 2026
- Lead sponsor
- West Virginia University
- Diseases
- Obesity
- NCT number
- NCT02879630
What you commit to
- Study type: Observational
- Participants enrolled: 13
- From 28 Nov 2016 to the primary completion date, 16 Feb 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Receipt of acyclovir or a pro-drug of acyclovir (valacyclovir, ganciclovir, valganciclovir, famciclovir) in the prior 24 hours
- Patients requiring ventilator support or vasopressors in the prior 24 hours
- Receipt of probenecid, mycophenolate, tenofovir, or zidovudine in the prior 7 days
- Prior inclusion in this study
Other illness
- Hypersensitivity to acyclovir
Lab values
- Serum creatinine \>1.5 mg/dL
Other
- Significant anatomical deformities that influence body habitus (i.e. amputation)
Who the study is looking for
- Age ≥18 years of age
- Receiving intravenous acyclovir 5 mg/kg (TBW for normal weight patients and ABW40 for obese patients) as part of their routine care
- Weight \> 190% of ideal body weight (IBW) for "obese" patients or weight 80-120% of IBW for matched control patients.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| West Virginia University Hospitals Coordinator of this site? Confirm its status | Morgantown | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.